# A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

> **NCT03000439** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 100 (actual)

## Conditions studied

- Arthritis Juvenile Idiopathic

## Interventions

- **DRUG:** In open-label phase: treatment with tofacitinib
- **DRUG:** In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

## Key facts

- **NCT ID:** NCT03000439
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-10
- **Primary completion:** 2024-03-27
- **Final completion:** 2024-03-27
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03000439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03000439, "A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03000439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*